MTSR - Metsera, Inc. Common Stock

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. The company is headquartered in New York, New York.

52W High

$47.40

52W Low

$12.30

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

8.30

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

13.07%

Institutions (25–75% balanced)

78.08%

Shares Outstanding

104,880,000

Float

64,514,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-03-31 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-2.53

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.7630

0.6950

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025